TD Asset Management Inc trimmed its holdings in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 28.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 30,110 shares of the company's stock after selling 11,690 shares during the quarter. TD Asset Management Inc's holdings in Doximity were worth $1,747,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in DOCS. FMR LLC grew its stake in shares of Doximity by 37.6% in the 4th quarter. FMR LLC now owns 9,409,313 shares of the company's stock valued at $502,363,000 after buying an additional 2,571,580 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Doximity in the first quarter valued at about $65,702,000. Invesco Ltd. lifted its holdings in shares of Doximity by 525.1% in the fourth quarter. Invesco Ltd. now owns 1,272,403 shares of the company's stock valued at $67,934,000 after purchasing an additional 1,068,849 shares in the last quarter. Fundsmith LLP acquired a new position in Doximity during the fourth quarter worth approximately $37,934,000. Finally, D. E. Shaw & Co. Inc. boosted its stake in shares of Doximity by 180.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 972,157 shares of the company's stock valued at $51,903,000 after purchasing an additional 625,467 shares during the period. 87.19% of the stock is currently owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, Director Kira Scherer Wampler sold 2,000 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $57.09, for a total transaction of $114,180.00. Following the completion of the sale, the director owned 16,618 shares in the company, valued at $948,721.62. The trade was a 10.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Regina M. Benjamin sold 10,000 shares of the company's stock in a transaction on Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the transaction, the director directly owned 16,618 shares in the company, valued at $997,080. This represents a 37.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,000 shares of company stock worth $1,825,940 in the last 90 days. Company insiders own 37.40% of the company's stock.
Analysts Set New Price Targets
A number of research firms recently weighed in on DOCS. Evercore ISI raised shares of Doximity from an "in-line" rating to an "outperform" rating and increased their price objective for the stock from $50.00 to $70.00 in a report on Wednesday, July 9th. Robert W. Baird lowered their target price on shares of Doximity from $87.00 to $65.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 20th. KeyCorp raised their price objective on shares of Doximity from $65.00 to $70.00 and gave the company an "overweight" rating in a research report on Monday, July 14th. BTIG Research upgraded shares of Doximity from a "neutral" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Monday, June 2nd. Finally, Raymond James Financial reduced their price objective on shares of Doximity from $83.00 to $65.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. Ten equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $65.26.
View Our Latest Report on DOCS
Doximity Stock Performance
Shares of NASDAQ:DOCS traded down $0.33 on Tuesday, hitting $57.97. The stock had a trading volume of 1,947,844 shares, compared to its average volume of 2,350,350. Doximity, Inc. has a twelve month low of $25.36 and a twelve month high of $85.21. The firm's 50 day moving average price is $58.53 and its 200-day moving average price is $59.92. The company has a market capitalization of $10.89 billion, a price-to-earnings ratio of 57.97, a price-to-earnings-growth ratio of 4.10 and a beta of 1.36.
Doximity (NASDAQ:DOCS - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.11. Doximity had a return on equity of 21.75% and a net margin of 36.60%. Doximity's revenue for the quarter was up 17.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.25 earnings per share. As a group, sell-side analysts predict that Doximity, Inc. will post 0.99 EPS for the current year.
Doximity Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Read More

Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.